Research programme: CD200-based therapeutics - Trillium Therapeutics

Drug Profile

Research programme: CD200-based therapeutics - Trillium Therapeutics

Alternative Names: Anti-CD 200 monoclonal antibodies; CD200 fusion protein; CD200Fc; TTI 200.7

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Trillium Therapeutics
  • Class Monoclonal antibodies; Proteins
  • Mechanism of Action CD200 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer
  • Discontinued Immunological disorders; Transplant rejection

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Canada (Parenteral)
  • 02 Jun 2014 Stem Therapeutics changes its name to Trillium Therapeutics
  • 11 Apr 2013 Trillium Therapeutics has merged with Stem Cell Therapeutics Corp.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top